acute myeloid leukemia

[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)] Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.

[Journal of Clinical Investigation] Scientists investigated the role of macrophage LC3-associated phagocytosis within the bone marrow microenvironment of acute myeloid leukemia.

[Oncolyze, Inc. (GlobeNewswire, Inc.)] Oncolyze, Inc, announced that the US FDA has granted the company orphan drug designation for its pipeline compound OM-301 for the treatment of acute myeloid leukemia. OM-301 is currently in pre-clinical development for AML and other cancers.

[Celularity, Inc.] Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).

[Cell Reports] Scientists found that selective AMP-activated protein kinase (AMPK)-activating compounds killed acute myeloid leukemia (AML) cells by rewiring mitochondrial metabolism that primed mitochondria to apoptosis by BH3 mimetics, holding therapeutic promise in AML.

[BMC Cancer] Investigators retrospectively collected the clinical data of 48 patients with mixed-lineage leukemia (MLL)-partial tandem duplications (PTD) acute myeloid leukemia or myelodysplastic syndrome with excess blasts who underwent allogeneic hematopoietic stem cell transplantation (HSCT) in Peking University People’s Hospital.